Lb Pharmaceuticals (LBRX) EPS (Basic) (2024 - 2026)

Lb Pharmaceuticals' EPS (Basic) history runs 3 years deep, the most recent figure standing at -$0.67 for Q1 2026.

• In Q1 2026, EPS (Basic) rose 95.44% year-over-year to -$0.67; the TTM figure through Mar 2026 stood at -$0.5 (changed N/A YoY), while the FY2025 annual figure was -$0.0, up 98.22% from the prior year.
• EPS (Basic) for Q1 2026 stood at -$0.67, down from $1.7 in the prior quarter.
• The five-year high for EPS (Basic) was $161.82 in Q4 2024, with the low at -$39.49 in Q3 2024.
• The 3-year median for EPS (Basic) is -$0.64 (2025), against an average of $17.99.
• Peak annual rise in EPS (Basic) reached 98.45% in 2025, while the deepest fall reached 98.95% in 2025.
• Lb Pharmaceuticals' EPS (Basic) stood at $161.82 in 2024, then sank by 98.95% to $1.7 in 2025, then slumped by 139.6% to -$0.67 in 2026.
• Business Quant data shows LBRX's EPS (Basic) at -$0.67 in Q1 2026, $1.7 in Q4 2025, and -$0.61 in Q3 2025.